Global Infantile Spasms Therapeutics Market - Industry Trends and Forecast to 2028

Запрос на TOC Запрос на TOC Обратиться к аналитику Обратиться к аналитику Бесплатный пример отчета Бесплатный пример отчета Узнать перед покупкой Узнать перед покупкой Купить сейчас Купить сейчас

Global Infantile Spasms Therapeutics Market - Industry Trends and Forecast to 2028

  • Pharmaceutical
  • Upcoming Report
  • Apr 2025
  • Global
  • 350 Pages
  • Количество таблиц: 220
  • Количество рисунков: 60

Обходите тарифные трудности с помощью гибкого консалтинга в области цепочки поставок

Анализ экосистемы цепочки поставок теперь является частью отчетов DBMR

Global Infantile Spasms Therapeutics Market

Размер рынка в млрд долларов США

CAGR :  % Diagram

Chart Image USD 4.18 Billion USD 8.96 Billion 2024 2032
Diagram Прогнозируемый период
2025 –2032
Diagram Размер рынка (базовый год)
USD 4.18 Billion
Diagram Размер рынка (прогнозируемый год)
USD 8.96 Billion
Diagram CAGR
%
Diagram Основные игроки рынка
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

Global Infantile Spasms Therapeutics Market, By Treatment (Anticonvulsants, Corticosteroids, Others), Type (Vigabatrin, Adrenocorticotropic Hormone, Phase III), Dosage (Solid, Liquid), Route of Administration (Oral, Parenteral, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028.

 Infantile Spasms Therapeutics MarketMarket Analysis and Insights : Global Infantile Spasms Therapeutics Market

Infantile spasms therapeutics market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 10% in the above mentioned forecast period.

Infantile spasm is a rare form of epilepsy which is also known as west syndrome. It is characterized by occurring of short and subtle seizures in infants. During a spasm, the body stiffens suddenly, arms, legs and head bend forward and the back may arch. Causes of this condition include brain tumors, birth injury, brain infection and genetic or chromosomal abnormalities.

Rise in the prevalence of infantile spasms, product innovation, growing number of births, advancement in technology, growing healthcare expenditure and growing government initiatives are the factors that will expand the infantile spasms therapeutics market. Rise in the research and development activities and pipelines drugs will provide beneficial opportunities for the infantile spasms therapeutics market in the forecast period of 2021-2028.

However, high cost of treatment, lack of proper diagnosis, complications associated with the disease and strict regulations for drug approval are the factors that will hinder the market growth and will further challenge the infantile spasms therapeutics market in the forecast period mentioned above.

This infantile spasms therapeutics market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the infantile spasms therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Infantile Spasms Therapeutics Market Scope and Market Size

The infantile spasms therapeutics market is segmented on the basis of treatment, type, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

  • On the basis of treatment, the infantile spasms therapeutics market is segmented into anticonvulsants, corticosteroids and others.
  • On the basis of type, the infantile spasms therapeutics market is segmented into vigabatrin, adrenocorticotropic hormone and phase III.
  • On the basis of dosage, the infantile spasms therapeutics market is segmented into solid and liquid.
  • On the basis of route of administration, the infantile spasms therapeutics market is segmented into oral, parenteral and others.
  • On the basis of end-users, the infantile spasms therapeutics market is segmented into clinic, hospital and others.
  • The infantile spasms therapeutics market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy and online pharmacy.

Infantile Spasms Therapeutics Market Country Level Analysis

Infantile spasms therapeutics market is analyzed and market size information is provided by the country, treatment, type, dosage, route of administration, end-users and distribution channel as referenced above.

The countries covered in the infantile spasms therapeutics market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.

North America dominates the infantile spasms therapeutics market due to the presence of major key players, early adoption of treatment procedure, innovation of new products, well-developed healthcare sector and continuous technological development in this region. Asia-Pacific is expected to grow during the forecast period of 2021-2028 due to the increasing research and development investments, rising investment in the healthcare sector, presence of large target patient pool, increase in the disposable income and growing government support.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Infantile spasms therapeutics market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Global Infantile Spasms Therapeutics Market Share Analysis

Infantile spasms therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to infantile spasms therapeutics market research.

The major players covered in the infantile spasms therapeutics market report are Anavex Life Sciences Corp., H. Lundbeck A/S, Catalyst Pharmaceuticals, Inc., GW Pharmaceuticals plc., Travere Therapeutics, Inc., Valerion Therapeutics, ORPHELIA Pharma, Mallinckrodt, Novartis AG, Sanofi, Pfizer Inc., Johnson & Johnson Private Limited, Abbott, Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., AstraZeneca, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited., Sumitomo Dainippon Pharma Co., Ltd., Biocon, Merck KGaA, and Cadila Pharmaceuticals, among other domestic and global players.  Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Интерактивная панель анализа данных
  • Панель анализа компании для возможностей с высоким потенциалом роста
  • Доступ аналитика-исследователя для настройки и запросов
  • Анализ конкурентов с помощью интерактивной панели
  • Последние новости, обновления и анализ тенденций
  • Используйте возможности сравнительного анализа для комплексного отслеживания конкурентов
Запросить демонстрацию

Методология исследования

Сбор данных и анализ базового года выполняются с использованием модулей сбора данных с большими размерами выборки. Этап включает получение рыночной информации или связанных данных из различных источников и стратегий. Он включает изучение и планирование всех данных, полученных из прошлого заранее. Он также охватывает изучение несоответствий информации, наблюдаемых в различных источниках информации. Рыночные данные анализируются и оцениваются с использованием статистических и последовательных моделей рынка. Кроме того, анализ доли рынка и анализ ключевых тенденций являются основными факторами успеха в отчете о рынке. Чтобы узнать больше, пожалуйста, запросите звонок аналитика или оставьте свой запрос.

Ключевой методологией исследования, используемой исследовательской группой DBMR, является триангуляция данных, которая включает в себя интеллектуальный анализ данных, анализ влияния переменных данных на рынок и первичную (отраслевую экспертную) проверку. Модели данных включают сетку позиционирования поставщиков, анализ временной линии рынка, обзор рынка и руководство, сетку позиционирования компании, патентный анализ, анализ цен, анализ доли рынка компании, стандарты измерения, глобальный и региональный анализ и анализ доли поставщика. Чтобы узнать больше о методологии исследования, отправьте запрос, чтобы поговорить с нашими отраслевыми экспертами.

Доступна настройка

Data Bridge Market Research является лидером в области передовых формативных исследований. Мы гордимся тем, что предоставляем нашим существующим и новым клиентам данные и анализ, которые соответствуют и подходят их целям. Отчет можно настроить, включив в него анализ ценовых тенденций целевых брендов, понимание рынка для дополнительных стран (запросите список стран), данные о результатах клинических испытаний, обзор литературы, обновленный анализ рынка и продуктовой базы. Анализ рынка целевых конкурентов можно проанализировать от анализа на основе технологий до стратегий портфеля рынка. Мы можем добавить столько конкурентов, о которых вам нужны данные в нужном вам формате и стиле данных. Наша команда аналитиков также может предоставить вам данные в сырых файлах Excel, сводных таблицах (книга фактов) или помочь вам в создании презентаций из наборов данных, доступных в отчете.

Часто задаваемые вопросы

The global Infantile Spasms Therapeutics market size was valued at USD 4.18 billion in 2024.
The global infantile spasms therapeutics market is to grow at a CAGR of 10% during the forecast period of 2025 to 2032.
The infantile spasms therapeutics market is segmented into six notable segments based on treatment, type, dosage, route of administration, end user, and distribution channel. On the basis of treatment, the market is segmented into anticonvulsants, corticosteroids and others. On the basis of type, the market is segmented into vigabatrin, adrenocorticotropic hormone, and phase III. On the basis of dosage, the market is segmented into solid and liquid. On the basis of route of administration, the market is segmented into oral, parenteral, and others. On the basis of end user, the market is segmented into clinic, hospital, and others. On the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy.
Companies such as Amneal Pharmaceuticals LLC (U.S.), Cipla (India), Endo, Inc. (U.S.), H. Lundbeck A/S (Denmark), Hetero (India), Intas Pharmaceuticals Ltd. (India), are the major companies in the infantile spasms therapeutics market.
In December 2022, Cerecin received U.S. FDA approval for its Investigational New Drug (IND) application for CER-001, a novel therapy for infantile spasms. This approval grants orphan drug designation, providing eligibility for market exclusivity and financial incentives. In January 2022, The FDA granted final approval for Sabril (vigabatrin) to treat infantile spasms in children aged 1 month to 2 years. Vigabatrin functions by preventing the breakdown of GABA in the brain, aiding in seizure control.
The countries covered in the infantile spasms therapeutics market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, and rest of Middle East and Africa.
The advancements in targeted therapies and neuroimaging technologies, is emerging as a pivotal trend driving the global infantile spasms therapeutics market.
The anticonvulsants segment is expected to dominate the global infantile spasms therapeutics market holding a major market share in 2025, due to their widespread use as first-line treatment, particularly vigabatrin, which is FDA-approved for infantile spasms and commonly prescribed for its efficacy in controlling seizure.
Asia-Pacific is the fastest growing region in the global infantile spasms therapeutics market due to expanding healthcare infrastructure, rising awareness about pediatric neurological disorders, and improving access to specialized care.
The major factors driving the growth of the infantile spasms therapeutics market are rising awareness and early diagnosis of pediatric neurological disorders, increased research and development investments in pediatric neurology, and the growing adoption of novel therapeutics.
The primary challenges include high treatment costs and limited access in low-income regions and delayed diagnosis due to symptom overlap.
U.S. is expected to dominate the global infantile spasms therapeutics market, particularly in the North America region. This dominance is attributed to its due to high awareness among healthcare providers and parents, widespread access to EEG and neuroimaging tools, and availability of approved therapies such as ACTH and vigabatrin.
North America is expected to dominate the global infantile spasms therapeutics market due to supported by a well-established healthcare infrastructure, early adoption of advanced diagnostic and treatment technologies, and strong presence of pediatric neurology specialists.
India is expected to witness the highest CAGR in the infantile spasms therapeutics market. This growth is driven by increased government initiatives, improving medical access in urban and semi-urban areas, and growing investments from global pharmaceutical companies.
Testimonial